Examining the efficacy of localised gemcitabine therapy for the treatment of pancreatic cancer using a hybrid agent-based model.
The prognosis for pancreatic ductal adenocarcinoma (PDAC) patients has not significantly improved in the past 3 decades, highlighting the need for more effective treatment approaches. Poor patient outcomes and lack of response to therapy can be attributed, in part, to a lack of uptake of perfusion o...
Main Authors: | Adrianne L Jenner, Wayne Kelly, Michael Dallaston, Robyn Araujo, Isobelle Parfitt, Dominic Steinitz, Pantea Pooladvand, Peter S Kim, Samantha J Wade, Kara L Vine |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2023-01-01
|
Series: | PLoS Computational Biology |
Online Access: | https://doi.org/10.1371/journal.pcbi.1010104 |
Similar Items
-
Pancreatic Cancer Chemoresistance to Gemcitabine
by: Manoj Amrutkar, et al.
Published: (2017-11-01) -
Gemcitabine Combination Nano Therapies for Pancreatic Cancer
by: Kamalika Samanta, et al.
Published: (2019-11-01) -
Review of molecular mechanisms underlying gemcitabine resistance in pancreatic cancer
by: A. Rajabpour, et al.
Published: (2017-10-01) -
Real-world outcomes of adjuvant gemcitabine gemcitabine plus capecitabine for resected pancreatic ductal adenocarcinoma
by: Sora Kang, et al.
Published: (2022-05-01) -
3D-Printed Coaxial Hydrogel Patches with Mussel-Inspired Elements for Prolonged Release of Gemcitabine
by: Sepehr Talebian, et al.
Published: (2021-12-01)